Potential IPF Therapy PXS-5382A Shows Potential in Phase 1 Trial

This topic contains 0 replies, has 1 voice, and was last updated by  Pulmonary Fibrosis News Moderator 9 months, 2 weeks ago.

  • Author
    Posts
  • #15548

    Phase 1 data show that Pharmaxis’ second LOXL2 inhibitor, PXS-5382A, is safe and holds potential to treat fibrotic diseases, including IPF. Click here to find out more.

    Did you know about this potential treatment? What are your thoughts on it?

You must be logged in to reply to this topic.

Copyright © 2017-2019 All rights reserved.

©2019 KLEO Template a premium and multipurpose theme from Seventh Queen

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending
or

Log in with your credentials

or    

Forgot your details?

or

Create Account